eli lilly

Insiders may sell shares for any number of reasons, but conventional wisdom is that insiders really only buy shares of a company for one reason -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who...

Eli Lilly (NYSE: LLY), which last week announced a deal to buy two imaging agents from Siemens (NYSE: SI) that could help aid the fight against Alzheimer's, is scheduled to report its first-quarter 2013 results Wednesday, April 24, before the markets open. Investors will be watching for the latest...

The earnings crunch is in full swing this week. Some of the highlights include anticipated quarterly reports from the likes of Apple, Amazon.com and Ford, which analysts expect to report lower per-share earnings for the most recent quarter than a year ago. On the other hand, year-over year...

“This is where money goes to die,” has described one sector over the past decade but this year, things are different. That industry is health care and for the first time since 1988, it leads the S&P with a 12 percent gain—the most among the 10 main groups. Specifically, health insurers,...

On Wednesday, Spectrum Pharmaceuticals (NASDAQ: SPPI) dropped 37 percent after releasing its Q1 and full year revenue guidance. The company said it expects sales of its colorectal cancer drug, Fusilev, to total $80 to $90 million in 2013 compared to $204 million in 2012. Seem like a huge drop...

A recent Australian study points toward possible good news in the search for answers regarding Alzheimer’s disease. The Border Mail reports that Australians will be among the first to test new drugs hoped to ward off Alzheimer’s after researchers discovered that the illness takes decades to...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...

In this morning's Marketwatch alert on companies that may report earnings surprises for the fourth quarter, just three were expected to offer positive surprises. Goldman Sachs (NYSE: GS) was seen beating the consensus estimate by up to 18 percent. Forest Laboratories (NASDAQ: FRX) could turn in a...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...

Bank of America Merrill Lynch offered some defensive stock picks for 2013 in a research report. Two drug makers and an REIT focused on health care facilities made the list. They were Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE) and Ventas (NYSE: VTR). Here is a quick look at how these three picks...

The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ...

It is not unusual for stocks on a tear to the overrun their mean price targets, which is a signal of how far analysts on average expect the share price to climb. Many of the top performing dividend payers in the health care sector over the past six months, such as Eli Lilly (NYSE: LLY) and PDL...

There are lots more on the earnings calendar this week, including results from Apple (NASDAQ: AAPL) for the three months that included the release of the iPhone 5. Monday Results from Caterpillar (NYSE: CAT) and Yahoo! (NASDAQ: YHOO) will be the highlights on Monday, and analysts expect to see...

The earnings crunch rolls on. Analysts are looking for strong earnings growth in this week's quarterly reports from Apple, Caterpillar, Starbucks and Visa. But ConocoPhillips, Ford and Netflix are among those expected to post significantly lower per-share earnings, compared to the same period of a...